Dova Pharmaceuticals Inc (DOVA.OQ)
18 Jan 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2017||Chairman of the Board|
|50||2017||President, Chief Executive Officer, Director|
|55||2017||Chief Financial Officer|
|39||2017||Senior Vice President - Product Development|
|65||2017||Chief Medical Officer|
- BRIEF-Dova Pharmaceuticals Inc - Supplemental NDA For Avatrombopag in ITP To Be Submitted In Second Half Of 2018
- BRIEF-Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review
- BRIEF-Dova Pharmaceuticals reports third quarter results
- BRIEF-Dova Pharmaceuticals announces New Drug Application submission to FDA
- BRIEF-Dova Pharmaceuticals qtrly net loss per share, basic and diluted $0.32